Neumora Reports Q4/FY25 Results, Strong Cash Runway, & Positive Pipeline Progress; NMRA-215 Study Delayed
NMRA has more than doubled off its 52-week low of $0.611.
Summary
Neumora Therapeutics reported Q4 and full-year 2025 financial results, showcasing a strong cash position expected to fund operations into Q3 2027, alongside positive clinical updates for multiple pipeline programs, though one program experienced a toxicology-related delay.
Key Events · Product Development and Regulatory · NMRA
-
Strong Cash Position and Runway
Neumora reported $182.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025, expected to fund operations into the third quarter of 2027.
-
Positive NMRA-511 Phase 1b Data
New data from a pre-specified analysis of the Phase 1b study for NMRA-511 in Alzheimer's disease agitation demonstrated strong effect sizes, reinforcing its potential best-in-class profile.
-
Navacaprant KOASTAL Studies Fully Enrolled
The KOASTAL-2 and -3 studies for navacaprant were fully enrolled in Q1 2026, with a joint topline data readout anticipated in the second quarter of 2026.
-
NMRA-898 Designated Lead Program
NMRA-898 was selected as the lead program in the M4 franchise for schizophrenia, based on promising clinical results from an ongoing Phase 1 study, including a long half-life and favorable tolerability.
Analysis · NMRA · Life Sciences
Neumora Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a robust cash position of $182.5 million, which is expected to fund operations into the third quarter of 2027. This provides significant financial stability for the clinical-stage biopharmaceutical company. The company also reported positive new Phase 1b data for NMRA-511 in Alzheimer's disease agitation, reinforcing its potential. Additionally, the KOASTAL-2 and -3 studies for navacaprant are fully enrolled with topline data expected in Q2 2026, and NMRA-898 was designated as the lead program in the M4 franchise based on promising Phase 1 results. However, the NMRA-215 obesity program faced a setback with unexpected adverse findings in a 13-week rat toxicology study, leading to a delay in clinical initiation to Q1 2027 as the study is being repeated. Despite this delay, the overall pipeline progress and strong financial runway present a positive outlook.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NMRA was trading at $2.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $389.3M. The 52-week trading range was $0.61 to $3.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.